Saybrook Capital NC Purchases 7,669 Shares of Kenvue Inc. $KVUE

Saybrook Capital NC raised its position in Kenvue Inc. (NYSE:KVUE) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 360,049 shares of the company’s stock after purchasing an additional 7,669 shares during the quarter. Kenvue accounts for about 2.1% of Saybrook Capital NC’s holdings, making the stock its 16th biggest holding. Saybrook Capital NC’s holdings in Kenvue were worth $7,536,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. GAMMA Investing LLC lifted its stake in shares of Kenvue by 33.2% in the first quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock worth $594,000 after acquiring an additional 6,169 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after acquiring an additional 4,034 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Kenvue in the first quarter worth approximately $246,000. Golden State Wealth Management LLC lifted its stake in shares of Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company’s stock worth $74,000 after acquiring an additional 2,295 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Kenvue by 2.6% in the first quarter. Robeco Institutional Asset Management B.V. now owns 103,091 shares of the company’s stock worth $2,472,000 after acquiring an additional 2,576 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 0.6%

Shares of Kenvue stock opened at $15.00 on Friday. The stock has a fifty day simple moving average of $17.91 and a 200 day simple moving average of $20.79. Kenvue Inc. has a 12-month low of $14.05 and a 12-month high of $25.17. The company has a market capitalization of $28.78 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. Kenvue’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.5%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is presently 112.16%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Citigroup lowered their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. UBS Group lowered their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.